– Experienced drug developer with a track record of building successful biopharmaceutical companies –
London, 20 July, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced the appointment of Dr. Bill Symonds as a Non-Executive Director of the Company. Bill brings experience in drug development and building biotech businesses gained over an accomplished and successful 30-year career in the industry.
“It is a huge pleasure to welcome Bill to our Board of Directors. He is an accomplished executive with expertise in bringing transformative therapies to market and building successful development organisations. Having developed and commercialised Sovaldi® and Harvoni®, the leading HCV treatments, Bill brings a deep understanding of drug development in advanced liver disease,” said Edward Hodgkin, Partner of Syncona Investment Management Limited who serves as Chairman and CEO of Resolution. “I look forward to working with Bill as Resolution grows into an industry-leading company with a pipeline of macrophage cell therapies designed to treat patients with liver cirrhosis.”
“I’m delighted to be joining Resolution at this important stage in the company’s growth,” added Bill Symonds. “The Company is the leader in the development of macrophage cell therapy for advanced liver disease, and I look forward to working with the experienced team to bring badly-needed treatments to patients with the potential to avoid the need for liver transplantation.”
Dr. Symonds currently serves as the Chief Executive Officer of Altavant Sciences and Enzyvant Sciences, both Sumitovant wholly-owned subsidiaries. Previously, Dr. Symonds was a member of the founding management team at Roivant Sciences, Inc., where he served as Chief Development Officer. Earlier in his career, Dr. Symonds held senior positions at a number of pharmaceutical companies, including Pharmasset, Inc. where he led the development of hepatitis C virus infection medicine Sovaldi®. Pharmasset was later acquired by Gilead where he continued to serve as VP Liver Disease Therapeutic Area and progressed Sovaldi® as well as Harvoni® through to FDA approval. Prior to Pharmasset, Dr. Symonds worked at GSK on numerous medicines for HIV infection. Dr. Symonds received his Doctor of Pharmacy from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York. He has authored or co-authored over 35 clinical articles and is named on nine patents related to the composition of matter and methods of use of drugs for hepatitis C infection.
– Ends –
- Further information:
+44 (0)7818 430877
Notes for Editors:
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com